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Abstract 
The non-mevalonate (methylerythritol phosphate, MEP) pathway for isoprenoid biosynthesis is essential in Plasmodium spp., 
but is absent in the human host. The pathway is a clinically validated antimalarial target on basis of studies with the antibiotic 
fosmidomycin, an inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr, IspC), which catalyses the first 
committed step of the MEP-pathway. In this review, we report on reverse, hydroxamate-based fosmidomycin analogues, which 
are studied by enzyme kinetics, parasite growth inhibition and crystallography in order to identify compounds with enhanced 
antiplasmodial activity. 
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1. Introduction 
 
Malaria is estimated to claim at least 600.000 lifes per year1. Classical drugs and insecticides used to control the 
disease and its vectors are subject to rapidly progressing attrition by the emergence and spread of parasite and vector 
resistance. There is thus an urgent need for novel antimalarial drugs, but none have been brought to the market in 
recent decades.  
The causative Plasmodium species have more than 5 000 genes, but the number of druggable targets is unknown. 
In order to counter the deleterious consequences of resistance spreading, it appears important to identify and study 
antimalarial drug targets that are not subject to cross-resistance with currently used antimalarial drugs. The non-
mevalonate isoprenoid biosynthesis pathway that was discovered in in the final years of the 20th century was 
immediately recognised as a potential therapeutic opportunity2,3. The pathway is essential in the malaria parasites for 
the biosynthesis of vitally important terpenoids but is absent in mammalian hosts who generates isoprenoids 
exclusively via the mevalonate pathway4,5; drugs addressing enzymes of the MEP pathway should therefore be 
exempt from target-related toxicity. Also of note, the enzymes of the non-mevalonate pathway are located in the 
apicoplast of malaria parasites, an ancient organelle that is believed to be evolutionarily related to plant chloroplasts; 
whereas apicoplasts host only small numbers of proteins, they are believed to comprise attractive drug targets6–8. 
The concept of targeting the non-mevalonate pathway of Plasmodium received a tremendous boost when Jomaa 
et al. showed in 1999 that the antibiotic fosmidomycin (cf. Fig. 2) inhibits IspC (Dxr)2, which catalyses the first 
committed step of the non-mevalonate pathway and is believed to be rate-limiting. More specifically, IspC catalyses 
a skeletal rearrangement of 1-deoxy-D-xylulose 5-phosphate (DOXP) and a subsequent reduction of the branched 
aldose intermediate, thus affording 2C-methyl-D-erithritol 4-phosphate (MEP). IspC requires a divalent cation 
(Mg2+ or Mn2+) and NADPH for catalytic activity (Fig. 1). 
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Fig. 1. IspC-catalysed conversion of DOXP to MEP. 
 
The antibiotic, fosmidomycin, which was initially isolated from Streptomyces lavendulae9,10, is a close structural 
analogue of the IspC substrate DOXP but carries a phosphonate residue instead of the phosphate residue of the 
enzyme substrate and is not subject to hydrolysis by cellular phosphatases11. Fosmidomycin had been under clinical 
development in the 1980s as an antibacterial agent but was subsequently abandoned due to its less than ideal 
pharmacokinetics9,10,12. However, due to the earlier pharmacological exploration, the compound could be rapidly 
admitted to several clinical studies conducted in Africa and Asia, which confirmed beyond doubt its potential to cure 
human malaria. Unfortunately, recrudescence of parasites was a frequent problem and the compound was shifted, in 
subsequent work, to combination treatment with clindamycin, an established antimalarial drug13–16. Even in the form 
of the combination therapy, the market introduction of fosmidomycin has not been accomplished. While mechanism 
of action and toxicity profile are favourable, the pharmacokinetic properties of the drug, with a plasma half-life of 
only about 2 h and a gastrointestinal absorption rate after oral administration of 20 % to 40 %, cause significant 
drawbacks17,18.  
The shortcomings of fosmidomycin that have so far hampered its market introduction, despite its apparent 
merits, have prompted attempts by several research groups to improve the structure activity relation by chemical 
modification19–29. These studies are based on a fairly thorough understanding of fosmidomycin’s mode of action 
including more than 50 X-ray structures of IspC orthologs from a variety of pathogenic and non-pathogenic species, 
in the absence of or in complex with substrates, coenzymes and/or inhibitors. Thus, it is clear that the phosphonate 
type terminus of fosmidomycin closely mimics the phosphate ester motif of the substrate, and the hydroxamate 
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moiety coordinates the essential divalent cation30–32. Notably, however, a flexible loop forms part of the active site 
cavity33, and the way from protein structure to the design of improved ligands is less than straightforward. 
 
 
 
Fig. 2. Fosmidomycin as lead structure and reverse analogues [26-29, 34, 40-42]. +: antiplasmodial activity, -: no or weak antiplasmodial activity  
3a, 4a, 5a: R = H, R’ = CH3;  3b, 4b, 5b: R = H, R’ = H; 3c, 4c, 5c: R = 4-CH3, R’ = CH3; 3d, 4d: R = 4-CH3, R’ = H; 3e, 4e: R = 4-
OCH3, R’ = CH3; 3f, 4f: R = 4-OCH3, R’ = H; 3g: R = 3,4-OCH3, R’ = CH3; 3h: R = 3,4-OCH3, R’ = H; 3i, 4i, 5i: R = 3,4-F, R’ = CH3; 
3j, 4j, 5j: R = 3,4-F, R’ = H; 3k, 4k, 5k: R = 3,4-Cl, R’ = CH3; 5l: R = 3,4-Cl, R’ = H; 3m, 4m, 5m: R = naphthalene-1-yl, R’ = CH3; 6a: 
R’ = CH3; 6b: R’ = H; 8a: R’ = CH2CH3; 8b: R’ = CH(CH3)2; 9a: R’ = CH3; 9b: R’ = H; 10a-b: n = 1, R’ = CH3 (10a), H (10b); 10c: n = 
2, R’ = CH2CH3; 10d-e: n = 3, R’ = CH3 (10d), H (10e); 12a: R’ = CH3; 12b: R’ = H; 13a: R’ = CH3; 13b: R’ = H.     
 
Structural modification of fosmidomycin was focused on four main areas: (i) replacement of the phosphonate 
motif by (bio)isosteres, synthesis of phosphonate prodrugs; (ii) replacement or modification of the hydroxamate 
moiety that chelates the catalytically essential divalent cation; (iii) modification of the aliphatic chain by 
introduction of (typically aromatic) substituents and (iv) modulation of the aliphatic linker between the anionic 
anchor group and the chelating head group (shortening, lengthening, isosteric replacement). The impact of the 
structural modification of the inhibitor can be monitored by enzyme kinetics using recombinant IspC from a variety 
of pathogens including Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli, by growth 
inhibition assays of P. falciparum, and by X-ray crystallography. Some results are summarized below. 
 
x The replacement of the phosphonate by (bio)isosteric moieties did not result in improved activity and was 
generally not a very encouraging approach. Several prodrugs displayed improved in vitro activity and in case of 
FR900098-prodrugs enhanced in vivo activity34–36. 
x The replacement of the hydroxamate motif by other chelating groups has not resulted in significantly improved 
activity37–39. Importantly, however, Rohmer et al.3 were the first to synthesize retroisosteric analogues of 
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fosmidomycin and FR900098 comprising a reoriented hydroxamate moiety. One compound was at least as active 
towards IspC from E. coli as the parent compound, FR90009822,34. Retroisosteric hydroxamates (short 
designation, (“reverse fosmidomycin analogues”) will be addressed in more detail below. 
x The introduction of aromatic side chains was first explored by Kurz et al.20  and later by Schlüter  et al.24  and 
afforded compounds with improved antiplasmodial activity. 
x Changing the distance between the phosphonate anchor and the chelator group typically abolished the inhibitory 
activity34,40.  
Subsequently, the two most promising approaches that had emerged from earlier investigations, namely the 
retroisosteric repositioning of the hydroxamate motif and the introduction of (substituted) aryl groups in the α 
position (α with respect to the phosphonate group) were combined. Moreover, the effect of N-substitution in the 
retroisosteric compound series was investigated28–30,40. Importantly, the retroisosteric series also enabled the detailed 
exploration of the isosteric replacement of a methylene group in the aliphatic linker by oxygen resp. sulphur       
(Fig. 2)41,42. By work with a thia isosteric compound, the enantioselectivity of IspC for a chiral, α phenylated 
derivative42 could be established. 
2. Results and discussion 
2.1.  Reverse fosmidomycin derivatives with α aryl substituents 
The synthesis of reverse hydroxamate derivatives of fosmidomycin carrying aryl substituents in the α position 
started from benzyl phosphonate esters resp. from benzaldehyde derivatives (Fig. 3, cf. Ref. 28 for details). Enzyme 
inhibition was studied using recombinant IspC from P. falciparum (PfIspC), M. tuberculosis (MtIspC) and E. coli 
(EcIspC). Specifically, the dehydrogenation of the coenzyme, NADPH, was monitored photometrically, and initial 
rates were extracted from individual progression curves. IC50 values were obtained using Dynafit software. Typical 
dose response curves are shown in Fig. 428,40–42.  
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Fig. 3. Stategies for preparation of reverse fosmidomycin analogues. 
 
Generally, the activity of reverse fosmidomycin derivatives against the Plasmodium enzyme exceeds that against 
the M. tuberculosis enzyme by about two orders of magnitude and the activity against the E. coli enzyme by about 
one order of magnitude. The inhibition of P. falciparum proliferation in erythrocytes was monitored by ELISA of 
histidine rich protein 2 (HRP2) using different parasite strains that were sensitive or resistant to chloroquine.         
A typical dose response curve is shown in Fig. 4.  
112   Claudia Lienau et al. /  Procedia Chemistry  14 ( 2015 )  108 – 116 
 
 
Fig. 4. Left, inhibition of IspC orthologs (Pf IspC, red; EcIspC, blue; MtIspC, green); Right, inhibiton of P. falciparum blood stages. Modified 
and reprinted with permission from reference40. Copyright 2014 American Chemical Society 
 
The in vitro antiplasmodial activity of the study compounds against different parasite strains was similar. Table 1 
compares the inhibition efficacy of isomeric pairs of fosmidomycin type resp. reverse fosmidomycin analogues. The 
activities of individual isomer pairs, as assessed against different parasite strains, differ by up to one order of 
magnitude but show no unequivocal trend. Moreover, pilot in vivo experiments with reverse hydroxamates using the 
P. berghei mouse model have shown some potential in the reverse carba series29.  
 
Table 1. Antiplasmodial activity (IC50) of isomeric hydroxamate and reverse hydroxamate pairs20, 24, 28, 40.  
 Hydroxamate Pf3D7 (nM) 
PfDd2 
(nM)  Reverse hydroxamate 
Pf3D7 
(nM) 
PfDd2 
(nM)  
14a 
 
550 350 3a 
 
90 74  
14b 
 
 400 3b 
 
400 570  
14c 
 
950 220 3c 
 
210 250  
14d 
 
850 270 3e 
 
100 300  
14e 
 
360 200 3f 
 
1 700 3 600  
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The IC50 values observed in the parasite growth assay showed good correlation with the enzyme inhibition 
effects, but were typically about one order of magnitude larger as compared to the IC50 values obtained in enzyme 
assays. Notably, however, the dose response curves observed in the parasite assays typically show a much steeper 
descent than the enzyme inhibition curves. Thus, at about 90 % inhibition level, the impact of the compounds is 
similar in the enzyme assays and growth assays (in terms of therapeutic potential, a steep curve shape for the 
inhibition of the living parasite is a definitive advantage since therapy is not targeted at 50 % reduction but at 
efficacious suppression of parasite growth)28,40–42. 
Fig. 5 shows the topology of fosmidomycin bound at the active site of PfIspC in comparison with the bound 
reverse fosmidomycin analogue 3e (Fig. 2; notably, the reverse analogue shown is considerably more bulky, due to 
its phenyl substituent). In both structures, the phosphonate moiety is coordinated by hydrogen bonds involving the 
backbone nitrogen as well as the β hydroxy group of Ser270. Moreover, in both structures, the phosphonate oxygens 
coordinate two water molecules. However, a significant difference in the embedding of the phosphonate motif arises 
by the implication of the respective side chains of His290 in case of fosmidomycin but of Ser306 in case of the 
reverse fosmidomycin analogue 3e40. In both structures under comparison, the magnesium ion coordinates both 
oxygen atoms of the respective hydroxamate motifs, even though their connectivities are changed. Moreover, in 
both structures, the coordination of the magnesium ion by the terminal carboxylate groups Asp231, Asp233 and 
Glu315 appears essentially invariant. The terminal amide group of Asn311 interacts with the phosphonate motif and 
also with the respective oxygen of the hydroxamate moiety. Also of note, Ser232 can form two hydrogen bonds with 
one of the hydroxamate oxygens in each respective structure under comparison. In summary, the comparison of 
these structures documents the considerable flexibility of the IspC active site that had been noted early on40.  
 
 
Fig. 5. Interactions of inhibitors in the active site of PfIspC. Metal coordination (2.0-2.1 Å) and possible hydrogen bonds (2.7-3.1 Å) are shown as 
solid and dashed lines, respectively. Intra- and intermolecular van der Waals contacts are shown as thin and thick gray arcs, respectively. 
(a) 3e complex. Residues uniquely involved in direct interactions with the bound inhibitor in the 3e complex are shown in blue. (b) 
Fosmidomycin  complex (R = H). Residues uniquely involved in direct interactions with the bound inhibitor in the fosmidomycin complex 
are shown in green. Reprinted with permission from reference40. Copyright 2014 American Chemical Society.  
 
2.2.  Oxa and thia isosters 
All attempts to replace the hydroxamate motif by other chelating motifs have hitherto resulted in loss of 
inhibitory activity. It has also been shown that decreasing or increasing the distance between the phosphanate anchor 
and the hydroxamate chelator is invariably detrimental. However, Verbrugghen et al.26 have shown that a methylene 
group connecting the phosphonate and hydroxamate moiety in FR900098 can be replaced by oxygen with impunity. 
In order to analyse in more detail the isosteric replacement of a methylene group by either oxygen or sulfur, it was 
preferable, for obvious technical reasons, to work with the reverse aryl derivatives. 
Specifically, in order to unequivocally assess the impact of the replacement of the β methylene group in α 
arylated reverse fosmidomycin derivatives, sets of compounds were synthesised, which differed exclusively by 
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carrying either methylene, oxygen or sulphur in the β position. All compounds were analysed using IspC from P. 
falciparum, M. tuberculosis and E. coli. In case of the P. falciparum enzyme, the carba compounds were stronger 
inhibitors than both the oxa and thia isosters. Conversely, with the enzymes from bacterial origin, the thia analogues 
were stronger inhibitors than the carba compounds whereas the oxa isosters also had a lower activity28,29,40–42.  
2.3. Enantioselectivity 
The thia analogue 5a (Fig. 2) in complex with PfIspC afforded an X-ray structure at a resolution of 2.0 Å where 
the electron-rich sulphur atom provides exceptionally good contrast for the molecular environment of the chiral 
center42. For the first time, the structure established unequivocally that the enzyme selectively binds the S-
enantiomer from the racemic mixture. 
The enantiomers of 5a were subsequently separated by chiral chromatography and were shown to differ by more 
than three orders of magnitude with respect to their IC50 values toward PfIspC (IC50, 9.4 nM resp. 12.000 nM). The 
combination of chromatographic resolution and crystal structure analysis assigned the more active enantiomer as 
the S-enantiomer. Notably, the enantiomer separation affords a formal increase of inhibitor activity by a factor of 
two42. 
3. Conclusion 
The seminal discovery of the natural products, fosmidomycin and FR900098, were made empirically in the 
1970s when even the existence of the non-mevalonate pathway was still unknown9,10,12. The natural product was 
assigned its target, IspC, in 1999, and the same paper also demonstrated that fosmidomycin could cure Plasmodium 
vinckei infected mice2. Work that had been done already in the 1980s, in context of the failed development of 
fosmidomycin as an antibacterial drug, facilitated the transition to clinical phase III studies documenting that 
fosmidomycin can cure human malaria.  
The partially successful repositioning of the abandoned antibacterial drug, fosmidomycin, as an antimalarial drug 
has triggered substantial efforts by academic and corporate groups to improve the activity profile of fosmidomycin 
by rational drug design. Most notably, the introduction of α aryl substituents improved the inhibitory potential both 
at the level of the isolated P. falciparum enzyme and of the parasite growth assay by at least one order of magnitude. 
In parallel, attempts to target other pathogens, notably M. tuberculosis, have resulted in several dozen research 
papers as well as at least 50 X-ray structures including several different IspC orthologs; near-atomic resolution of 
1.65 Å has been achieved. The resolutions of currently available X-ray structures of the P. falciparum enzyme 
extend to 1.86 Å. However, the data presented in this paper have also shown that work with the living parasite is an 
important complement to work at the molecular dimension. 
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